SAN DIEGO, March 23, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of James S. Mazzola as vice president, Corporate Communications and Investor Relations, reporting to President and CEO Dr. Helen Torley.
Mr. Mazzola will be responsible for the creation and implementation of integrated communication and branding efforts that support Halozyme's business objectives to all key stakeholders, including investors, employees, media, corporate partners, patients, clinicians and the scientific community.
"As we grow our business, Jim will play a key role helping to shape our brand, support our investor outreach and align our marketing communication efforts across all stakeholders," said Dr. Torley. "His background makes him a strong complement to the very senior management team we have been building to drive results in our product programs, make a difference in the lives of patients and continue to create value for shareholders."
Mr. Mazzola brings nearly 25 years of public relations, financial communication and marketing communication experience to Halozyme. He was previously senior vice president of Global Marketing, Communication and Investor Relations for CareFusion, responsible for the company's integrated marketing, communication and brand strategy, investor relations, sales operations and serving as president of the CareFusion Foundation. Prior to joining CareFusion, he was senior vice president of Global Communication at Cardinal Health where he led corporate public relations, financial communication and the Cardinal Health Foundation. At Dell, he held roles of increasing responsibility, including managing all product communication and supporting communication programs for Chairman and CEO Michael Dell. He began his career at NCR Corp., and earned his BA in Communication and MBA from the University of Dayton.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, our investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events, competitive conditions and the continuation of the Halozyme-Janssen and other collaborations. These and other factors that may result in differences are discussed in greater detail in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2015.